Senti Biosciences, Inc. announced plans to streamline its business operations, including reducing its workforce by approximately 37%, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.288 USD | -3.87% | -10.78% | -56.36% |
May. 17 | Senti Biosciences, Inc. Announces Executive Changes | CI |
May. 09 | Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-56.36% | 13.18M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Spark Therapeutics, Inc. Announces Workforce Reduction